Evolution of Novartis’ Small Molecule Screening Deck Design von Schuffenhauer, Ansgar, Schneider, Nadine, Hintermann, Samuel, Auld, Douglas, Blank, Jutta, Cotesta, Simona, Engeloch, Caroline, Fechner, Nikolas, Gaul, Christoph, Giovannoni, Jerome, Jansen, Johanna, Joslin, John, Krastel, Philipp, Lounkine, Eugen, Manchester, John, Monovich, Lauren G, Pelliccioli, Anna Paola, Schwarze, Manuel, Shultz, Michael D, Stiefl, Nikolaus, Baeschlin, Daniel K

Volltext

mRNA Display Identifies Potent, Paralog-Selective Peptidic Ligands for ARID1B von Cremosnik, Gregor S., Mesrouze, Yannick, Zueger, Patrik, Furkert, David, Grandjean, Frédéric, Argoti, Dayana, Mermet-Meillon, Fanny, Bauer, Matthias R., Brittain, Scott, Rogemoser, Phuong, Yang, Winnie, Giovannoni, Jerome, McGregor, Lynn, Tang, Jenny, Knapp, Mark, Holzinger, Sandra, Buhr, Sylvia, Muller, Lionel, Leder, Lukas, Xie, Lili, Fernandez, Cesar, Nieto-Oberhuber, Cristina, Chène, Patrick, Galli, Giorgio G., Sesterhenn, Fabian

Volltext

Abstract P124: JDQ443, a covalent irreversible inhibitor of KRAS G12C, exhibits a novel binding mode and demonstrates potent anti-tumor activity and favorable pharmacokinetic prope... von Brachmann, Saskia M., Weiss, Andreas, Guthy, Daniel A., Beyer, Kim, Voshol, Johannes, Maira, Michel, Prahallad, Anirudh, Porta, Diana Graus, Schnell, Christian, Ostermann, Nils, Vaupel, Andrea, Gerspacher, Marc, Leblanc, Catherine, Erdmann, Dirk, Sterker, Dario, Kerr, Grainne, Jerome, Giovannoni, Head, Victoria, Stringer, Rowan, De Kanter, Ruben, Jeff, Kearns, Roman, Danielle, Widmer, Toni, Wessels, Peter, Nunez, Eloisa Jimenez, Sedrani, Richard, Zecri, Frederic, Hofmann, Francesco, Engleman, Jeff, Lorthiois, Edwige, Cotesta, Simona

Volltext

Solid-phase synthesis of 3,7-disubstituted perhydro-1,4-diazepine-2,5-diones from amino acids and β-amino acids von Giovannoni, Jérôme, Subra, Gilles, Amblard, Muriel, Martinez, Jean

Volltext

Synthesis and Structure of Symmetrical Bicyclic Hexapeptides Bridged by Metathesis Reaction von Giovannoni, Jérôme, Didierjean, Claude, Durand, Philippe, Marraud, Michel, Aubry, André, Renaut, Patrice, Martinez, Jean, Amblard, Muriel

Volltext

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis von Montalban, Xavier, Hauser, Stephen L, Kappos, Ludwig, Arnold, Douglas L, Bar-Or, Amit, Comi, Giancarlo, de Seze, Jérôme, Giovannoni, Gavin, Hartung, Hans-Peter, Hemmer, Bernhard, Lublin, Fred, Rammohan, Kottil W, Selmaj, Krzysztof, Traboulsee, Anthony, Sauter, Annette, Masterman, Donna, Fontoura, Paulo, Belachew, Shibeshih, Garren, Hideki, Mairon, Nicole, Chin, Peter, Wolinsky, Jerry S

Volltext

Efficacy of Frexalimab on Physical and Psychological Impacts and Fatigue in Relapsing Multiple Sclerosis: Findings from MSIS-29v2 and PROMIS-Fatigue-MS-8a Assessments in a Phase 2... von Vermersch, Patrick, Saubadu, Stephane, Truffinet, Philippe, Arnould, Benoit, Hakimi-Hawken, Natalia, Minor, Charles, Araujo, Lita, Gourlain, Samuel, Msihid, Jerome, Giovannoni, Gavin

Volltext

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials von Giovannoni, Gavin, Kappos, Ludwig, Seze, Jerome, Hauser, Stephen L., Overell, James, Koendgen, Harold, Manfrini, Marianna, Wang, Qing, Wolinsky, Jerry S.

Volltext

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlle... von Foley, John F, Defer, Gilles, Ryerson, Lana Zhovtis, Cohen, Jeffrey A, Arnold, Douglas L, Butzkueven, Helmut, Cutter, Gary, Giovannoni, Gavin, Killestein, Joep, Wiendl, Heinz, Smirnakis, Karen, Xiao, Shan, Kong, George, Kuhelj, Robert, Campbell, Nolan, van der Walt, Anneke, Dwyer, Christopher, Buzzard, Katherine, Spies, Judith, Parratt, John, van Pesch, Vincent, Willekens, Barbara, Perrotta, Gaetano, Bartholomé, Emmanuel, Grand'Maison, Francois, Jacques, Francois, Giacomini, Paul, Vosoughi, Reza, Girard, Jean-Marc, de Seze, Jerome, Lebrun Frenay, Christine, Ruet, Aurelie, Laplaud, David-Axel, Reifschneider, Gerd, Wagner, Bert, Rauer, Sebastian, Pul, Refik, Seipelt, Maria, Berthele, Achim, Klotz, Luisa, Kallmann, Boris-Alexander, Paul, Friedemann, Achiron, Anat, Lus, Giacomo, Centonze, Diego, Patti, Francesco, Grimaldi, Luigi, Hupperts, Raymond, Frequin, Stephan, Fermont, Jiske, Madueno, Sara Eichau, Alonso Torres, Ana Maria, Costa-Frossard França, Lucienne, Meca-Lallana, Jose Eustasio, Ruiz, Luis Brieva, Pearson, Owen, Rog, David, Evangelou, Nikolaos, Ismail, Azza, Lathi, Ellen, Fox, Edward, Leist, Thomas, Sloane, Jacob, Wu, Gregory, Khatri, Bhupendra, Steingo, Brian, Thrower, Ben, Gudesblatt, Mark, Calkwood, Jonathan, Bandari, Daniel, Scagnelli, John, Laganke, Christopher, Robertson, Derrick, Kipp, Lucas, Belkin, Martin, Cohan, Stanley, Goldstick, Lawrence, Courtney, Ardith, Vargas, Wendy, Sylvester, Andrew, Srinivasan, Jayshri, Kannan, Meena, Picone, Maryann, English, Jeffrey, Napoli, Salvatore, Balabanov, Roumen, Zaydan, Islam, Nicholas, Jacqueline, Kaplan, Jeffrey, Lublin, Fred, Riser, Emily, Miller, Tamara, Alvarez, Enrique, Wray, Sibyl, Gross, Jeffrey, Pawate, Siddharama, Hersh, Carrie, McCarthy, Lucas, Crayton, Heidi, Graves, Jennifer

Volltext

Long-term Reduction of Confirmed Disability Progression and Time to Walking Aid After 6 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis (1847) von Giovannoni, Gavin, Kappos, Ludwig, de Seze, Jerome, Hauser, Stephen, Overell, James, Koendgen, Harold, Prajapati, Kalpesh, Manfrini, Marianna, Wang, Qing, Wolinsky, Jerry

Volltext

The tomato genome sequence provides insights into fleshy fruit evolution von Tomato Genome Consortium, Sato, S, Guigó Serra, Roderic, Cámara, Francisco, Gianese, S

Volltext

Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study (S49.001) von Montalban, Xavier, Hemmer, Bernhard, Rammohan, Kottil, Giovannoni, Gavin, De Seze, Jerome, Bar-Or, Amit, Arnold, Douglas, Sauter, Annette, Masterman, Donna, Fontoura, Paulo, Garren, Hideki, Chin, Peter, Wolinsky, Jerry

Volltext

Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Primary Progressive Multiple Sclerosis in the ORATORIO Trial (P4.384) von Wolinsky, Jerry, Montalban, Xavier, Kappos, Ludwig, Hauser, Stephen, Giovannoni, Gavin, de Seze, Jerome, Bar-Or, Amit, Masterman, Donna, Bernasconi, Corrado, Wei, Wei, Garren, Hideki, Chin, Peter, Belachew, Shibeshih, Arnold, Douglas

Volltext

Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis (P7.017) von Montalban, Xavier, Hemmer, Bernhard, Rammohan, Kottil, Giovannoni, Gavin, De Seze, Jerome, Bar-Or, Amit, Arnold, Douglas, Sauter, Annette, Leppert, David, Chin, Peter, Garren, Hideki, Wolinsky, Jerry

Volltext

Alemtuzumab Suppresses MRI Disease Activity Over 6 Years in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Res... von Schippling, Sven, Traboulsee, Anthony, Barnett, Michael, Comi, Giancarlo, De Sèze, Jérôme, Giovannoni, Gavin, Pelletier, Daniel, Rovira, Alex, Margolin, David H, Thangavelu, Karthinathan, Arnold, Douglas L

Volltext

Réduction à long terme du taux de poussées et de progression du handicap confirmée à 48 semaines (CDP48) après 6,5 ans de traitement par ocrelizumab (OCR) chez des patients atteint... von Giovannoni, Gavin, Kappos, Ludwig, De Sèze, Jérôme, Hauser, Stephen L., Köndgen, Harold, Schneble, Hans-Martin, Wolinsky, Jerry S.

Volltext

Réduction à long-terme du taux de poussées et de progression du handicap après 6 ans de traitement par ocrelizumab (OCR) chez des patients atteints de sclérose en plaques récurrent... von De Sèze, Jérôme, Giovannoni, Gavin, Kappos, Ludwig, Hauser, Stephen L., Köndgen, Harold, Prajapati, Kalpesh, Wolinsky, Jerry S.

Volltext

Efficacité et sécurité de l’ocrelizumab chez les patients atteints de sclérose en plaques primaire progressive : résultats d’ORATORIO, étude de phase III, en double-insu, contrôlée... von De Seze, Jérôme, Arnold, Douglas, Giovannoni, Gavin, Montalban, Xavier, Sauter, Annette, Chin, Peter, Wolinsky, Jerry

Volltext

The prevalence of Sjögren syndrome in patients with primary progressive multiple sclerosis von Fox, Robert J

Volltext